I asked artificial intelligence (AI) about your question. This is how AI explained it:
-----------------------
Yes, the situation described is common and medically expected when treating inflammatory conditions like Polymyalgia Rheumatica (PMR) or Rheumatoid Arthritis (RA) with Kevzara (sarilumab).

Here is the breakdown of why this happens:
1. CRP is an Indirect Marker
C-reactive protein (CRP) is produced by the liver in response to inflammatory cytokines, particularly Interleukin-6 (IL-6). It is a downstream marker, meaning it tells you that inflammation was present, but it does not directly measure the active immune cells or the tissue damage itself.

2. Kevzara Drops CRP Rapidly
Kevzara is an IL-6 receptor antagonist. It blocks the signaling of IL-6, which is the primary driver for the liver to produce CRP. When you start Kevzara, you are cutting off the signal to the liver, causing CRP levels to plummet or "normalize" very quickly, often within two weeks.

Crucial Point: A low or normal CRP while on Kevzara means the liver has stopped producing CRP, but it does not mean the underlying autoimmune disease (the inflammation in your joints or muscles) is completely gone.